Semax

Common questions about Semax

What is Semax?

Semax is a synthetic heptapeptide based on a fragment of adrenocorticotropic hormone (ACTH 4-10) with a C-terminal Pro-Gly-Pro extension. It is studied in Russian neurology research for neuroprotection and cognitive-enhancement endpoints.

Is Semax FDA-approved?

No. Semax is not approved by the FDA, MHRA, Health Canada, or the TGA. It has been used clinically in Russia under the regulatory framework of the Russian Federation, but Western research-peptide vendors sell it strictly as a research compound.

What is the half-life of Semax?

Pepticker does not publish a quantitative plasma half-life for Semax — published Russian pharmacokinetic data are not as readily available as for prescription peptides, and ranges reported in the literature vary by route and assay method.

What dose of Semax is used in research?

Doses reported in published Russian studies vary by route (intranasal is most common) and endpoint. Pepticker does not publish a dosing protocol — refer to the original literature for the model you are reproducing.

What is Semax commonly stacked with?

Semax is most often discussed alongside Selank in the published Russian neuropeptide literature, with researchers studying combined or sequential protocols across cognitive and anxiolytic endpoints.

Is Semax legal?

Semax is sold for research use in the US, Canada, and the UK. In Australia it is TGA Schedule 4 and personal import is tightly controlled. Status is informational — not legal advice.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.